Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model
- PMID: 11745776
- DOI: 10.1002/jps.1076
Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model
Abstract
The aim of this study was to predict the disposition of midazolam in individual surgical patients by physiologically based pharmacokinetic (PBPK) modeling and explore the causes of interindividual variability. Tissue-plasma partition coefficients (k(p)) were scaled from rat to human values by a physiologically realistic four-compartment model for each tissue, incorporating the measured unbound fraction (f(u)) of midazolam in the plasma of each patient. Body composition (lean body mass versus adipose tissue) was then estimated in each patient, and the volume of distribution at steady state (V(dss)) of midazolam was calculated. Total clearance (CL) was calculated from unbound intrinsic CL, f(u), and estimated hepatic blood flow. Curves of midazolam plasma concentration versus time were finally predicted by means of a perfusion-limited PBPK model and compared with measured data. In a first study on 14 young patients undergoing surgery with modest blood loss, V(dss) was predicted with an only 3.4% mean error (range -24-+39%) and a correlation between predicted and measured values of 0.818 (p < 0.001). Scaling of k(p) values by the four-compartment model gave better predictions of V(dss) than scaling using unbound k(p). In the PBPK modeling, the mean +/- standard deviation (SD) prediction error for all data was 9.7 +/- 33%. In a second study with 10 elderly patients undergoing orthopedic surgery, hemodilution and blood loss led to a higher f(u) of midazolam. The PBPK modeling correctly predicted a marked increase in V(dss), a smaller increase in CL, and a prolonged terminal half-life of midazolam, as compared with findings in the first study. Interindividual variation in the disposition of midazolam could thus in part be related to the physiological characteristics of the patients and the f(u) of the drug in their plasma.
Copyright 2001 Wiley-Liss, Inc. and the American Pharmaceutical Association
Similar articles
-
Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs.Br J Clin Pharmacol. 2005 Jun;59(6):691-704. doi: 10.1111/j.1365-2125.2004.02225.x. Br J Clin Pharmacol. 2005. PMID: 15948934 Free PMC article.
-
The Constraints, Construction, and Verification of a Strain-Specific Physiologically Based Pharmacokinetic Rat Model.J Pharm Sci. 2017 Sep;106(9):2826-2838. doi: 10.1016/j.xphs.2017.05.003. Epub 2017 May 8. J Pharm Sci. 2017. PMID: 28495566
-
Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models.J Pharmacokinet Pharmacodyn. 2003 Aug;30(4):285-307. doi: 10.1023/a:1026194618660. J Pharmacokinet Pharmacodyn. 2003. PMID: 14650375
-
Considering Age Variation When Coining Drugs as High versus Low Hepatic Extraction Ratio.Drug Metab Dispos. 2016 Jul;44(7):1099-102. doi: 10.1124/dmd.115.067595. Epub 2016 Feb 10. Drug Metab Dispos. 2016. PMID: 26864786 Review.
-
Physiologically Based Pharmacokinetic Modeling of Nanoparticles.J Pharm Sci. 2019 Jan;108(1):58-72. doi: 10.1016/j.xphs.2018.10.037. Epub 2018 Oct 29. J Pharm Sci. 2019. PMID: 30385282 Free PMC article. Review.
Cited by
-
Projection of exposure and efficacious dose prior to first-in-human studies: how successful have we been?Pharm Res. 2008 Apr;25(4):713-26. doi: 10.1007/s11095-007-9411-4. Epub 2007 Sep 25. Pharm Res. 2008. PMID: 17899327
-
Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion.J Pharmacokinet Pharmacodyn. 2010 Dec;37(6):591-615. doi: 10.1007/s10928-010-9185-x. Epub 2010 Dec 14. J Pharmacokinet Pharmacodyn. 2010. PMID: 21153869 Review.
-
Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.Clin Pharmacokinet. 2010 Apr;49(4):239-58. doi: 10.2165/11318130-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20214408
-
A quantitative systems pharmacology approach, incorporating a novel liver model, for predicting pharmacokinetic drug-drug interactions.PLoS One. 2017 Sep 14;12(9):e0183794. doi: 10.1371/journal.pone.0183794. eCollection 2017. PLoS One. 2017. PMID: 28910306 Free PMC article.
-
Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic Patients.Clin Pharmacokinet. 2017 Jul;56(7):759-779. doi: 10.1007/s40262-016-0475-3. Clin Pharmacokinet. 2017. PMID: 28039606
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources